Introduction: Although engineered T-cell-based antitumor immunotherapy using tumor-
antigen-specific T-cell receptor (TCR) gene transfer is undoubtedly a promising strategy, a …

Development of CD8+ T-cell responses targeting tumor-associated antigens after
autologous stem cell transplantations (ASCTs) might eradicate residual tumor cells and …

Adoptive cell therapy using tumor-reactive T lymphocytes is a promising approach for
treating advanced cancer. Successful tumor eradication depends primarily on the expansion …

We designed a whole tumor cell vaccine by “loading” lymphoma tumor cells with CG-
enriched oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9). CpG …

Previously we have shown that vaccination with the poorly immunogenic B16BL6‐D5
melanoma (D5) elicits a dominant type 2 (T2) cytokine response that fails to protect the host …

Immunotherapies that augment antitumor T cells have had recent success for treating
patients with cancer. Here we examined whether tumor‐specific CD 4+ T cells enhance CD …

Modern chemotherapy regimens and supportive care have produced remarkable
improvements in the overall survival of patients with hematologic malignancies. However …

Adoptively transferred antigen-specific T cells that recognize tumor antigens through their
native receptors have many potential benefits as treatment for virus-associated diseases …

In recent years, several clinical trials have involved the vaccination of cancer patients with
tumor-specific antigens that are recognized by T lymphocytes. Anti-vaccine T-cell responses …

The recognition by effector T lymphocytes of novel antigenic targets on tumor cells is the
premise of specific, targeted immunotherapy of cancer. With the molecular characterization …